Abstract
This program discussed the rationale for treatment choices in non-Hodgkin lymphoma and HER-2 positive breast cancer. The mechanisms and management of infusion, cytokine-mediated, and allergic reactions related to monoclonal antibody (MOAB) therapy were covered, as well as a summary of the mechanisms of action and toxicities of MOAB therapy in breast cancer.
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Breast Neoplasms / genetics
-
Breast Neoplasms / therapy*
-
Drug Delivery Systems / methods
-
Epidermal Growth Factor / drug effects
-
Epidermal Growth Factor / genetics
-
Genes, erbB-2 / drug effects
-
Genes, erbB-2 / genetics
-
Humans
-
Lymphoma, Non-Hodgkin / therapy*
-
Oncology Nursing / methods
-
Patient Education as Topic
-
Vascular Endothelial Growth Factor A / drug effects
-
Vascular Endothelial Growth Factor A / genetics
Substances
-
Antibodies, Monoclonal
-
Vascular Endothelial Growth Factor A
-
Epidermal Growth Factor